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ABSTRACT: New multicomponent solid forms of Sildenafil have been discovered by means of a 
combined virtual/experimental cocrystal screening. Coformer selection of candidates was conducted 
based on an in silico screening method from a database of more than 2000 organic compounds and the 
intensive experimental screen produced 23 new solid forms. Since the 12 coformers chosen have a 
combination of phenol and carboxylic acid groups a variety of cocrystals, salts and hybrid 
salt/cocrystals were discovered and characterized.  
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INTRODUCTION 
Cocrystals of Active Pharmaceutical Ingredients (APIs) have received a massive attention over the 
last decade because they offer many opportunities to improve physicochemical properties of drugs.
1,2
 
Indeed, solubility is one of the most important properties for a drug compound since it has a direct 
impact on the bioavailability and the cocrystal approach is a versatile toolbox to tune this and another 
important property
3,4
 such as stability
5
 because the high number of available potential coformers. 
On february 2018, FDA released a final guidance titled “Regulatory Classification of Pharmaceutical 
Co-Crystals Guidance for Industry”,6 providing applicants planning to submit new drug applications 
with information on the regulatory classification of pharmaceutical cocrystals, with a similar treatment 
to that of a new polymorph, and not as a new API. FDA asks the applicants to provide evidences to 
demonstrate that “both the API and coformers are present in the unit cell” and “the component API and 
coformer co-exist in the cocrystal which interact nonionically”. The FDA guidance suggests the 
applicant to consider the difference of ΔpKa between the API and the coformer or to provide evidences 
that proton transfer has not ocurred in the lattice by means of spectroscopic tools or other orthogonal 
approaches. Thus, from a regulatory point of view it is very important to assess the proton transfer in a 
multicomponent drug solid form. In this sense, hybrid salt/cocrystals are located in the middle of the 
salt/cocrystal continuum and can constitute a particular case to be considered during the formulation of 
a new solid form.
7
 
Sildenafil, the active principle of Viagra, is the first oral drug used for the medical treatment of 
erectile dysfunction in elderly patients and it was initially used as an antihypertensive drug
8, 9
 but due to 
its poor aqueous solubility and low bioavailability it is generally formulated as sildenafil citrate.
10
 This 
solid form still exhibits moderate bioavailability and this is the reason why some efforts have been 
conducted to discover new salts and cocrystals with enhanced physicochemical properties. In this sense, 
a sildenafil/acetylsalicylic cocrystal exhibiting enhanced intrinsic dissolution rate compared to sildenafil 
 3 
citrate has been reported. Moreover, pharmacokinetics of salts and cocrystals of sildenafil with 
dicarboxylic acids has been studied and the glutarate salt was revealed to be a good candidate for 
alternative formulation of the citrate salt.
11
 The crystal structures of sildenafil base, sildenafil citrate 
monohydrate and sildenafil saccharinate have been published in the literature
12
 and some of us have 
described a new polymorph of Sildenafil free base and new solvates.
13,14
 With the aim to discover new 
multicomponent forms and extend the solid state knowledge of this important API we have conducted a 
combined virtual/experimental salt/cocrystal screening by using a broad set of thermodynamic and 
kinetic experimental conditions. 23 new solid forms of sildenafil, including salts, cocrystals and hybrid 
salt/cocrystals, have been discovered and some of their crystal structures solved.  
  
Figure 1. Molecular structure of sildenafil. 
 
2 MATERIALS AND METHODS 
2.1. Materials  
Sildenafil (SIL) used in this study was of reagent grade and used as received from Polpharma (form I). 
The coformers quercetin (QUE), methyl gallate (MEG), tartaric acid (TAR), 3-hydroxybenzoic acid (3-
HBA), 4-hydroxybenzoic acid (4-HBA), resorcinol (RES), 3,4-dihydroxybenzoic acid(3,4-DHBA) and 
caffeic acid (CAF) where purchased from Sigma-Aldrich. 
2.2 Methods 
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2.2.1 Virtual Cocrystal Screening: For each compound, the molecule was drawn in an extended 
conformation and energy minimised using the molecular mechanics methods implemented in 
TorchLite.
15
 Gaussian 09 was used to optimise the geometry and calculate the MEPS on the 0.002 Bohr 
Å
-3
 electron density isosurface using DFT and a B3LYP/6-31G* basis set.
16
 The MEPS was converted 
into SSIPs using in-house software.
17
 
2.2.2 Cocrystal Screening: Screening through liquid assisted grinding experiments (LAG) was 
conducted by grinding 20-35 mg of a 1:1 mixture of SIL and each coformer together with one drop of 
different solvents using a Retsch MM 2000 grinding mill. The samples were placed in 2 mL volume 
stainless steel jars, along with two stainless tungsten grinding balls of 3 mm diameter. Grinding was 
performed for 15-30 minutes, with a frequency of the mill of 30 Hz. Finally, the samples were collected 
immediately without prior drying for PXRD analysis. The formation of a new solid form was 
determined by comparing PXRD patterns of starting materials and products from cocrystal screening 
LAG experiments. Screening through reaction crystallization (RC) was conducted by preparing a 
saturated solution of the most soluble component (SIL or coformer) in different solvents in a sealed vial 
under stirring. A small quantity of the less soluble component was added until it did not dissolve 
anymore. The suspension was stirred at different times and the resulting solids were filtered and 
analyzed by PXRD. Screening through solvent mediated transformations (SMT) were conducted by 
preparing suspensions of SIL and coformer in different molar ratios (40-1200 mg of the final mixture) in 
selected solvents. The sealed vials were stirred for different times and the resulting solids were filtered 
and analyzed by PXRD. 
2.2.3 Solution Crystallization: Solutions of SIL:coformer in a 1:1 molar ratio (10-20 mg of the final 
mixture) were prepared in different solvents and heated up in a heating stainless steel block. The heater 
was switched off and the solutions were allowed to slowly cool down to room temperature inside the 
heating block. The samples which did not crystallize were tightly sealed and kept at 25 ºC until 
precipitation was observed. 
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2.2.4 Synthesis of the different crystal forms of Sildenafil 
Details of synthesis and characterization of each form can be found at ESI section. Stoichiometry has 
been assessed based on NMR and TGA measurements when crystal structure is not available. In those 
cases where crystal structure has not been solved the definition of the form as a salt or a cocrystal has 
been done based on the probability of proton transfer determined with equation 3. 
2.2.4.1 Quercetin cocrystal (1:1) isopropanol solvate (SIL-QUE) I. It was obtained by reaction 
crystallization in IPA, (m.p. 140 ºC). Its PXRD diagram has been indexed. 
2.2.4.2 Quercetin cocrystal (1:1) tetrahydrofuran solvate (SIL-QUE) II. It was obtained by solvent 
mediated transformation in THF, (m.p. 143 ºC). Its PXRD diagram has been indexed. 
2.2.4.3 3,4-dihydroxybenzoic acid salt (1:1) isopropanol solvate (SIL-3,4-DHBA) I. It was obtained 
by solvent mediated transformation in IPA, (m.p 105 ºC). Its PXRD diagram has been indexed. 
2.2.4.4 3,4-Dihydroxybenzoic acid acid hybrid salt-cocrystal (1:2) acetonitrile solvate (SIL-3,4-
DHBA) II. It was obtained by slow evaporation in ACN at 25 ºC, (3 days). 
2.2.4.5 3,4-Dihydroxybenzoic acid hybrid salt-cocrystal (1:2) acetonitrile solvate (SIL-3,4-DHBA) 
III. It was obtained by solvent mediated transformation in acetonitrile, (m.p 99 ºC). Its PXRD diagram 
has been indexed. 
2.2.4.6 3,4-Dihydroxybenzoic acid hybrid salt-cocrystal (2:3) dihydrate (SIL-3,4-DHBA) IV. It was 
obtained by slow evaporation in IPA at 25 ºC, (3 days). 
2.2.4.7 Resorcinol cocrystal (1:1) (SIL-RES) I. It was obtained by solvent mediated transformation in 
IPA, (m.p 117 ºC). Its PXRD diagram has been indexed. 
2.2.4.8 Resorcinol cocrystal (1:2) (SIL-RES) II. It was obtained by solvent mediated transformation in 
xylene, (m.p 152 ºC). Its PXRD diagram has been indexed. 
2.2.4.9 Tartaric acid salt (1:1) (SIL-TAR) I. It was obtained by liquid assisted grinding in IPA. Its 
PXRD diagram has been indexed. 
2.2.4.10 Tartaric acid salt (2:1) (SIL-TAR) II. It was obtained by solvent mediated transformation in 
THF, (m.p 152 ºC). Its PXRD diagram has been indexed. 
2.2.4.11 Tartaric acid salt (1:1) isopropanol solvate (SIL-TAR) III. It was obtained by solvent 
mediated transformation in IPA, (m.p 229 ºC). Its PXRD diagram has been indexed. 
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2.2.4.12 Tartaric acid salt (2:1) isopropanol solvate (SIL-TAR) IV. It was obtained by slow 
evaporation in IPA/THF at 25 ºC, (3 days).  
2.2.4.13 Caffeic acid salt (2:3) monohydrate (SIL-CAF) I. It was obtained by solvent mediated 
transformation in ACN, (m.p. 165 ºC). Its PXRD diagram has been indexed. 
2.2.4.14 Caffeic acid salt (2:3) (SIL-CAF) II. It was obtained by heating SIL-CAF I at 100 ºC under 
N2 atmosphere, (m.p. 164 ºC).  
2.2.4.15 Methyl gallate cocrystal (1:1) (SIL-MEG). It was obtained by reaction crystallization in 
ACN, (m.p. 135 ºC). Its PXRD diagram has been indexed. 
2.2.4.16 3-Hydroxybenzoic acid salt (1:1) acetonitrile solvate (SIL-3-HBA) I. It was obtained by 
reaction crystallization in ACN, (m.p. 161 ºC). 
2.2.4.17 3-Hydroxybenzoic acid salt (1:1) tetrahydrofuran solvate sesquihydrate (SIL-3-HBA) II. 
It was obtained by slow evaporation in THF at 25 ºC, (53 days). 
2.2.4.18 3-Hydroxybenzoic acid salt (1:1) (SIL-3-HBA) III. It was obtained by solvent mediated 
transformation in IPA, (m.p. 156 ºC). 
2.2.4.19 3-Hydroxybenzoic acid hybrid salt-cocrystal (2:3) dihydrate (SIL-3-HBA) IV. It was 
obtained by slow evaporation in ACN at 25 ºC, (51 days). 
2.2.4.20 4-Hydroxybenzoic acid salt (1:1) (SIL-4-HBA) I. It was obtained by liquid assisted grinding 
in ACN. 
2.2.4.21 4-Hydroxybenzoic acid salt (1:1) (SIL-4-HBA) II hemiisopropanol solvate. It was obtained 
by reaction crystallization in IPA, (m. p. 136 ºC). 
2.2.4.22 4-Hydroxybenzoic acid salt (1:1) (SIL-4-HBA) III. It was obtained by reaction crystallization 
in ACN, (m. p. 107 ºC). 
2.2.4.23 4-Hydroxybenzoic acid salt (1:1) tetrahydrofuran solvate (SIL-4-HBA) IV. It was obtained 
by solvent mediated trandformation in THF, (m.p. 130ºC). 
2.2.5 X-ray crystallographic analysis.  
Single crystal X-ray diffraction intensity data of the different crystal forms of Sildenafil were collected 
using a D8 Venture system equipped with a multilayer monochromator and a Mo microfocus (λ = 
 7 
0.71073 Å). Frames were integrated with the Bruker SAINT software package using a SAINT 
algorithm. Data were corrected for absorption effects using the multi-scan method (SADABS).
18
 The 
structures were solved and refined using the Bruker SHELXTL Software Package, a computer program 
for automatic solution of crystal structures and refined by full-matrix least-squares method with ShelXle 
Version 4.8.0, a Qt graphical user interface for SHELXL computer program.
19
  
Powder X-ray diffraction patterns were obtained on a PANalytical X’Pert PRO MPD diffractometer in 
transmission configuration using Cu Kα1+2 radiation (λ = 1.5406 Å) with a focusing elliptic mirror and 
a PIXcel detector working at a maximum detector’s active length of 3.347. Configuration of 
convergent beam with a focalizing mirror and a transmission geometry with flat sample sandwiched 
between low absorbing films measuring from 2 to 40º in 2θ, with a step size of 0.026 or from 2 to 70º 
in 2θ, with a step size of 0.013 with measuring times of 30 minutes to 4 hours. The powder 
diffractograms were indexed and the lattice parameters were reﬁned by means of LeBail ﬁts by means 
of Dicvol04,
20
 and the space groups were determined from the systematic absences. A summary of 
crystal data and relevant refinement parameters are given in Tables 1 and 2. 
 
 
 
 8 
Table 1. Crystal data for the different crystal forms of sildenafil 
Structure SIL-TAR IV SIL-3,4-DHBA II SIL-3,4-DHBA IV SIL-3-HBA II SIL-3-HBA IV 
Empirical formula C51H74N12O15S2 C40H48N8O12S C65H82N12O22S2 C31H43N6O9S C65H82N12O19S2 
Formula Weight 1159.34 864.92 1447.54 675.77 1399.54 
Temperature (K) 293(2) 100(2) 100(2) 100(2) 100(2) 
Crystal system Triclinic Monoclinic Monoclinic Monoclinic Monoclinic 
space group P-1 P21/n P21/c P21/n P21/n 
a, b, c (Å) 
6.3796(8) 
13.4449(18) 
17.620(2) 
11.6418(8) 
15.3849(13) 
24.7913(19) 
17.6070(17) 
8.6938(8) 
24.942(2) 
17.7205(18) 
8.2574(7) 
22.991(2) 
17.5329(10) 
8.6545(4) 
22.9653(13) 
α, β, γ (°) 
108.607(5) 
98.363(6) 
92.814(6) 
90 
102.749(3) 
90 
90 
117.101(5) 
90 
90 
102.748(3) 
90 
90 
105.591(2) 
90 
Volume (Å
3
) 1409.7(3) 4330.8(6) 3398.7(5) 3281.2(5) 3356.5(3) 
Z, Density (calc.) (Mg/m
3
) 1, 1.366 4, 1.327 2, 1.414 4, 1.368 2, 1.385 
Crystal size (mm
3
) 0.344 x 0.144 x 0.044 0.358 x 0.196 x 0.074 0.324 x 0.152 x 0.112 0.129 x 0.119 x 0.109 0.336 x 0.197 x 0.086 
Reflections collected /  
unique 
53107 / 6455  
[R(int)=0.1123] 
66326 / 8875  
[R(int)=0.0949] 
69444 / 7838   
[R(int)=0.0722] 
18923 / 4567  
 [R(int)=0.082] 
33777 / 5726   
[R(int)=0.0482] 
Data / restraints / 
parameters 
6455 / 8 / 396 8875 / 0 / 570 7838 / 2 / 460 4567 / 6 / 454 5726 / 0 / 502 
Goodness-of - fit on F
2
 1.105 1.070 1.024 1.017 1.038 
Final R índices 
 [I > 2σ(I)] 
R1=0.0678, 
 wR2=0.1740 
R1=0.0537,  
wR2=0.1151 
R1=0.0476,   
 wR2=0.1084 
R1=0.0504,   
 wR2=0.1168 
R1=0.0382,    
wR2=0.0886 
CCDC 1858573 1858576 1858577 1858574 1858575 
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Table 2. Comparative cell parameters data
a
 from SXRD and PXRD  
Crystal form a (Å) b (Å) c (Å) α (°) β (°) γ (°) V (Å3) Z R (%) Space group 
SIL-QUE I PXRD 42.39(2) 14.854(4) 15.059(6) 82.41(3) 138.08(2) 120.01(2) 4992(3) 5 11.1 P-1 
SIL-QUE II PXRD 22.528(8) 13.536(4) 8.007(2) 57.95(2) 95.99(3) 95.96(2) 2054(1) 2 6.69 P-1 
SIL-3,4-DHBA I PXRD 12.765(2) 13.463(1) 12.106(2) 112.03(1) 84.0929(9) 114.28(1) 1754.7(3) 2 8.41 P-1 
SIL-3,4-DHBA II SXRD 11.6418(8) 15.3849(13) 24.7913(19) 90 102.749(3) 90 4330.8(6) 4 5.37 P21/n 
SIL-3,4-DHBA III PXRD 24.947(6) 15.718(3) 11.642(3) 90 103.96(2) 90 4430(2) 4 7.76 P21/n 
SIL-3,4-DHBA IV SXRD 17.6070(17) 8.6938(8) 24.942(2) 90 117.101(5) 90 3398.7(5) 2 4.76 P21/c 
SIL-RES I PXRD 11.266(2) 14.835(2) 14.178(2) 38.099(7) 94.79(1) 96.09(9) 1453.9(3) 2 12.0 P-1 
SIL-RES II PXRD 14.2705(4) 26.083(2) 9.9925(5) 90 108.398(3) 90 3530.0(3) 4 6.20 P21/a 
SIL-TAR I PXRD 18.07(1) 13.609(6) 7.590(4) 85.98(3) 92.33(3) 110.09(4) 1749(1) 2 7.31 P-1 
SIL-TAR II PXRD 33.57(9) 15.070(3) 11.547(3) 90 90 90 5445(2) 4 8.11 P21 21 21 
SIL-TAR III PXRD 18.313(4) 15.070(3) 6.3764(9) 63.85(1) 101.56(1) 112.86(2) 1454.5(5) 2 7.64 P-1 
SIL-TAR IV SXRD 6.3796(8) 13.4449(18) 17.620(2) 108.607(5) 98.363(6) 92.814(6) 1409.7(3) 1 6.78 P-1 
SIL-CAF I PXRD 25.845(7) 8.336(1) 20.32(6) 90 121.19(1) 90 3744(2) 2 5.76 P21/m 
SIL-MEG PXRD 12.9869(8) 13.4289(8) 13.4551(8) 53.033(3) 118.580(4) 111.246(4) 1637.1(1) 2 5.04 P-1 
SIL-3-HBA II SXRD 17.7205(18) 8.2574(7) 22.991(2)
 
90 102.748(3) 90 3281.2(5) 4 5.04 P21/n 
SIL-3-HBA IV SXRD 17.5329(10) 8.6545(4) 22.9653(13) 90 105.591(2) 90 3356.5(3) 2 3.82 P21/n 
a
 R-Factor for SXRD and Rwp for PXRD. 
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2.2.6 Differential Scanning Calorimetry (DSC). Differential scanning calorimetry analysis was 
carried out by means of a Mettler-Toledo DSC-822e calorimeter. Experimental conditions: aluminium 
crucibles of 40 L volume, atmosphere of dry nitrogen with 50 mL/min flow rate, heating rate of 
10C/min. The calorimeter was calibrated with indium of 99.99% purity (m.p.: 156.4 ºC 
ΔH: 28.55 J/g). 
2.2.7 Thermogravimetric Analysis (TGA). Thermogravimetric analyses were performed on a Mettler-
Toledo TGA-851e thermobalance. Experimental conditions: alumina crucibles of 70 L volume, 
atmosphere of dry nitrogen with 50 mL/min flow rate, heating rate of 10C/min. 
2.2.8 Nuclear magnetic resonance (NMR): Proton nuclear magnetic resonance (
1
H-NMR) spectra has 
been recorded on a Varian Mercury 400 (400 MHz). Chemical shifts for proton are reported in parts per 
million (ppm) downfield from tetramethylsilane and are referenced to residual proton in the NMR 
solvent (dmso-d6: 2.50). Experimental conditions: delay: 1; pulse: 45º; scans: 32 or 64. 
2.2.9 Dissolution Study 
The dissolution measurements were carried out for pure sildenafil, salts of sildenafil with citric acid, 
tartaric acid and 3-HBA, a cocrystal with RES, QUE and three hybrid salt-cocrystals (HSC) of sildenafil 
with 3,4-DHBA. The dissolution was determined in 0.1N HCl (pH 1.2), phosphate buffer pH 6.5 and a 
biorelevant dissolution medium Fasted State Simulated Intestinal Fluid (FaSSIF) at 25°C. For 
dissolution studies 40 mg crystalline compounds were added to the dissolution medium stirred at 100 
rpm over 24 hours and samples were withdrawn at 1 hour and 24 hours. The amount of SIL dissolved in 
1 hour (D1hr) and 24 hours (D24hrs) was determined using HPLC technique. The details about dissolution 
medium and HPLC method are provided in SI.  
3 RESULTS AND DISCUSSION 
3.1 Virtual cocrystal screen 
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We have selected the coformers for experimental screening based on the virtual cocrystal screening 
methodology developed by some of us to predict the probability of cocrystal formation. This 
computational tool has been validated using experimental data extracted from the literature.  
The difference between the energy of the cocrystal and the pure components was used to rank CCFs, 
and CCFs that were found to form cocrystals experimentally were significantly enriched at the top of the 
ranked list in most cases.
21
 This approach uses Surface Site Interaction Points (SSIPs) calculated from 
the ab initio molecular electrostatic potential surface (MEPS) of the isolated molecule in the gas 
phase.
17,22
 The interaction of a molecule with its environment is described by a discrete set of SSIPs, 
each represented by an interaction parameter, i, which is positive for a H-bond donor site (or positive 
region on the MEPS) and negative for a H-bond acceptor site (or negative region on the MEPS). The 
energy of interaction between two SSIPs, i and j, is given by the product ij. We assume that pairwise 
interactions between SSIPs are optimised in a solid, and this provides a method for evaluating the 
interaction site pairing energy of a solid without knowledge of the crystal structure.
23
 The most positive 
SSIP is paired with the most negative SSIP, the next most positive SSIP with the next most negative, 
and so on, giving a hierarchical list of interactions.
24,25
 This interaction site pairing strategy provides a 
straightforward method for estimating the energy of a solid, E (equation 1). The same approach can be 
used to estimate the energy of a cocrystal, and the difference between the interaction site pairing 
energies of the cocrystal and the pure components, ∆E, can be used to estimate the probability of 
cocrystal formation (equation 2).   
 E = eie jå     (1) 
 
DE =-(Ecc -E1 -E2)   (2) 
where E1, E2 and Ecc are the interaction site pairing energies of the pure solids, 1 and 2, and a cocrystal 
respectively. Note that this definition means that ∆E is always positive, and a large value indicates a 
high probability of cocrystal formation. 
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Some of us have previously applied the method to successfully predict the formation of new cocrystals 
(references) and in this work we have followed this theoretical approach to guide the selection of a 
limited number of coformers to test experimentally. Thus, the difference between the interaction site 
pairing energies of the 1:1 cocrystal and the pure components of a database which contains more than 
2400 organic compounds (including 860 products from the GRAS list) was calculated for each 
sildenafil/coformer combination using equations 1 and 2, and the coformers were ranked in order of 
decreasing ∆E. Finally, only 12 coformers were arbitrarily chosen among the top 100 compounds 
according to toxicity criteria and Table 3 shows them along with their corresponding ΔE values. 
 
 
Figure 2: SSIPs calculated for sildenafil. Blue spheres correspond to H-bond donors and red spheres to H-bond acceptors. 
 
Table 3. Coformers chosen in this study based on the difference between the interaction site pairing 
energies of sildenafil and the pure components, ΔΕ.  
Coformer 
 
 
ΔΕ / kJ mol-1 
Quercetin -28,1 
Resveratrol -24,0 
Phloroglucinol -23,8 
3,4-Dihydroxybenzoic acid -21,7 
Resorcinol -19,3 
Tartaric acid -18,2 
Caffeic acid -17,8 
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Myo-inositol -15,7 
tert-Butylhydroquinone -13,8 
Methyl gallate -13,5 
3-Hydroxybenzoic acid -13,1 
4-Hydroxybenzoic acid -12,9 
  
 
Since sildenafil has a strong basic group, the formation of salts with strong carboxylic acids is 
expected. In fact, the formation of a salt or a cocrystal can be assessed based on the “rule of thumb”26 
which states that salts are formed when ΔpKa [pKa(base) – pKa(acid)] ≥ 3 and a cocrystal is expected 
when this value is ≤ 0, being the combinations with a value 0 ≤ [pKa(base) – pKa(acid)] ≤ 3 much less 
reliable and falling around a “salt-cocrystal continuum” region.27 This uncertainty motivated the 
analysis and correlation by Cruz-Cabeza
28
 of a big set of experimental cocrystal/salt data in order to 
develop a more reliable equation to predict the salt/cocrystal outcome. According to this statistical 
analysis, equation 3 allows to predict the probability of proton transfer around the region of ΔpKa 
values between -1 and 4. 
P (%) = 17 ΔpKa + 28                       (3) 
Sildenafil has a basic functional group (piperazine) with a pKa value of 6.78
29
 and we have applied 
this statistical approach to the coformers with acidic groups selected from the virtual cocrystal screening 
to assess the probability of salt formation (Table 4). 
 
Table 4. Cocrystal screening coformers pKa’s and estimated probability of proton transfer 
Coformer Reported pKa ΔpKa P (%) 
Quercetin 8,4530 -1,67 0 
Resveratrol 8,4931 -1,71 0 
Phloroglucinol 7,9732 -1,19 8 
3,4-dihydroxybenzoic acid 4,4032 2,38 68 
Resorcinol 9,4432 -2,66 0 
Tartaric acid 3,0332 3,75 92 
Caffeic acid 4,4732 2,31 67 
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Myo-inositol 12,2931 -5,51 0 
tButylhydroquinone 9,9431 -3,16 0 
Methyl gallate 8,1131 -1,33 5 
3-Hydroxybenzoic acid 4,0833 2,7 74 
4-Hydroxybenzoic acid 4,5733 2,21 66 
 
Coformers with acidic groups such as (3-hydroxybenzoic acid, 4-hydroxybenzoic acid, caffeic acid, 
3,4-dihydroxybenzoic acid and tartaric acid) were expect to form salts. However, salt stoichiometry is 
an important outcome not always easy to predict because hybrid salt-cocrystal forms are also possible. 
In this sense, there are interesting examples in the literature with unexpected stoichiometries due to the 
presence of non-ionized molecules in the crystal structure such as the p-coumaric acid / quinine
34
 or the 
trans-N,N′-Dibenzyldiaminocyclohexane / 2,3-dichlorophenylacetic acid35 hybrid salt–cocrystals. 
Moreover, Aakeröy etal
36
 suggested in a structural analysis of more than 80 cocrystals and salts formed 
between carboxylic acids and N-heterocycles that the formation of unexpected hybrid salt–cocrystals 
could be due to the fact that carboxylate moieties are not readily satisfied by a single hydrogen-bond 
donor making necessary the presence of neutral carboxylic acids in the crystal structure. We have 
examined the Cambridge Structural Database (Version 5.39, 2018) in order to assess the formation of 
hybrid salt-cocrystal forms in multicomponent crystals containing a piperazine ring (the basic group of 
sildenafil) and a carboxylic acid (fig 3).  
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CH2
CH2
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Figure 3: Fragments searched in multicomponent crystals in the CSD 
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A total of 247 crystal structures containing atomic coordinates were found and classified as salt, 
cocrystal or hybrid salt/cocrystal according to the C-O bond lenghts of the carboxylate moiety. 
Although 184 structures showed total proton transfer between donor and acceptor 63 of them revealed 
that cocrystals or mixed salt/cocrystals were formed. This encouraged us to test the carboxylic acids 
previously chosen in the virtual cocrystal prediction. Table 5 summarizes the results of this structural 
analysis.  
Table 5. Classification of Multicomponent crystals with a piperazine and a carboxylic group in the 
CSD 
Class No. of structures % 
Salt 184 75 
Cocrystal 38 15 
Hybrid 25 10 
 
3.2 Salt/Cocrystal screening 
With the aim to discover new salts or cocrystals of Sildenafil an extensive multicomponent solid 
forms screening was conducted by using a broad set of thermodynamic and kinetic experimental 
conditions from a variety of 54 solvents
37
 which produced 194 individual crystalline solids (see ESI for 
experimental and characterization details). 
 
3.3 Crystal structures analysis 
The crystal structures of 5 out of the new 23 forms of sildenafil have been solved by Single Crystal X-
ray Diffraction and the following analysis shows that in all cases salts and hybrid salt/cocrystals have 
been formed with tartaric acid, 3-hydroxybenzoic acid and 3,4-dihydroxibenzoic acid. 
 
3.3.1 Tartaric acid salt isopropanol hemisolvate (SIL-TAR-IV) 
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Tartaric acid salt isopropanol hemisolvate crystallizes with one molecule of sildenafil cation, half 
molecule of tartrate dianion and half disordered molecule of isopropanol in the asymmetric unit. 
Transfer of both protons of tartaric acid has been deduced since tartrate C-O distances are 1.18 and 1.23 
Å. The dianion, which shows disorder between two conformations (in a 1:1 ratio), is encapsulated 
between two molecules of sildenafil establishing strong charge-assisted hydrogen bonds. 
Sildenafil/tartrate cages are packed with a combination of electrostatic interactions between 
sulphonamide moieties in a self-association fashion and weak hydrogen bonds between N-
methylpyrazole rings (fig. 4 and 5). Molecular cavities are present and occupied by disordered 
molecules of isopropanol. 
 
Figure 4: Crystal structure of tartaric acid salt of sildenafil (he tret isopropanol hemisolvate). The most relevant interactions 
have been highlighted. Channels filled by solvent molecules are highlighted with grey circles.  
 17 
 
Figure 5: Sildenafil/tartrate cage in the crystal structure of tartaric acid salt of sildenafil (he tret isopropanol hemisolvate). 
 
3.3.2 Hybrid 3-hydroxybenzoic acid salt/cocrystal monohydrate (SIL-3-HBA-IV) 
The hybrid salt/cocrystal formed by 3-hydroxybenzoic acid and sildenafil crystallizes with one molecule 
of sildenafil cation, one molecule of the carboxylate, half molecule of the carboxylic acid and one 
molecule of water in the asymmetric unit. Chains of self-assembled sildenafil cations are formed 
through strong hydrogen bonds between the piperazinium ring and the carbonylic oxygen. As expected, 
strong charge-assisted hydrogen bonds are formed between the carboxylate anion and the piperazinium 
cation but one molecule of the non-ionized carboxylic acid interacts with the carboxylate anion via the 
phenol and carboxylic hydrogen in an alternate manner (fig. 9). Weak antiparallel dipole-dipole 
interactions between stacked pyrimidinone rings are established conferring extra stabilization to the 
crystal (fig 8). 
In addition, one molecule of water is also present acting as a bridge between carboxylates (fig. 6). Non-
ionized 3-hydroxybenzoic acid molecules are located in channels stablishing strong hydrogen bonds 
with other 3-hydroxybenzoate molecules (fig. 7). 
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Figure 6: Chains of carboxylate/carboxylic acid molecules linked by molecules of water in the hybrid 3-hydroxybenzoic 
salt/cocrystal monohydrate 
 
3.3.3 3-hydroxybenzoic acid salt THF hemisolvate sesquihydrate (SIL-3-HBA II) 
The salt formed by 3-hydroxybenzoic acid and sildenafil crystallizes with one molecule of sildenafil 
cation, one molecule of the carboxylate, half disordered molecule of THF and 1.5 molecules of water in 
the asymmetric unit. In spite of the different degree of proton transfer this solid form is isostructural to 
the hybrid 3-hydroxybenzoic acid salt/cocrystal and the same interactions between sildenafil and 3-
hydroxybenzoate molecules are stablished. Moreover, identical channels are formed but filled by 
disordered tetrahydrofurane and water molecules instead of molecules of 3-hydroxybenzoic acid. Only 
small differences between both structures are present like, for instance, centroid-centroid distances 
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measured between pyrimidinone rings and torsion angles of propyl groups (fig. 8). 
 
Figure 7: Representation of the crystal structures of 3-hydroxybenzoic acid salt and hybrid salt/cocrystal of sildenafil. The 
most relevant interactions have been highlighted and hydrogens have been partially omitted for clarity. Channels filled by 
THF and water molecules in the salt or 3-hydroxybenzoic molecules in the hybrid salt/cocrystal are highlighted with grey 
circles 
 
 20 
Figure 8: Antiparallel dipole-dipole interactions established between stacked pyrimidinone rings in the crystal structures of 
3-hydroxybenzoic acid salt (right) and hybrid salt/cocrystal (left). Differences in centroid-centroid distances measured 
between pyrimidinone rings and torsion angles of propyl groups are shown for each structure. 
 
3.3.4 Hybrid 3,4-dihydroxybenzoic acid salt/cocrystal monohydrate (SIL-3,4-DHBA IV) 
The hybrid salt/cocrystal formed by 3,4-dihydroxybenzoic acid and sildenafil crystallizes with one 
molecule of sildenafil cations, one molecule of the carboxylate, half molecule of the carboxylic acid and 
one molecule of water in the asymmetric unit. This solid form is isostructural to the hybrid 3-
hydroxybenzoic acid salt/cocrystal. The presence of an extra phenol group in the 3,4-dihydroxybenzoic 
acid only reinforces the same packing without disrupting any of the main observed interactions in the 
hybrid 3-hydroxybenzoic acid salt/cocrystal. Figure 9 shows chains of carboxylate molecules linked by 
water molecules in both structures. 
 
Figure 9: Chains of carboxylate molecules linked by molecules of water in the hybrid 3-hydroxybenzoic acid salt/cocrystal 
(left) and in the hybrid 3,4-dihydroxybenzoic acid salt/cocrystal (right). 
 
3.3.5 Hybrid 3,4-dihydroxybenzoic acid salt/cocrystal acetonitrile disolvate (SIL-3,4-DHBA II) 
The hybrid 3,4-dihydroxybenzoic acid salt/cocrystal acetonitrile disolvate crystallizes with one 
molecule of the sildenafil cation, one molecule of the carboxylate, one molecule of the carboxylic acid 
and two molecules of acetonitrile in the asymmetric unit. In a similar way that the tartaric acid salt, 
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instead of catemeric chains of sildenafil cations, self-assembled dimers are formed through charge-
assisted hydrogen bonds (fig. 10). 
 
Figure 10. Crystal structure of 3,4-dihydroxybenzoic acid hybrid salt/cocrystal. Self-assembled dimers formed through 
charge-assisted hydrogen bonds are highlighted. Hydrogens have been partially omitted for clarity. 
 
However, the antiparallel dipole-dipole interactions between stacked pyrimidinone rings are not 
observed in this form. This is the only structure of this family of hybrid salts/cocrystals where water is 
not present and this produces a different architecture of the coformer self-assembling which consists of 
layers of alternate carboxylic/carboxylate interactions (fig. 11).  
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Figure 11: Layers of alternate carboxylic (blue)/carboxylate (red) interactions. 
 
3.4 Dissolution study  
The dissolution studies were carried out at pH 1.2, pH 6.5 and FaSSIF (pH 6.5) which represent the 
average pH values of the fast state stomach and intestine respectively. SIL has pH dependent solubility 
which decreases with increase in pH. One of the major challenges in the dissolution study of 
multicomponent entities is continuous change in the solution composition due to precipitation of either 
of the component over dissolution testing period. The solubility data generated may be erroneous due to 
limitations of the analytical method for example estimations carried out by UV spectrophotometry are 
subject to the overlap in the absorption spectra of the two components. We have used HPLC method to 
quantify amount of SIL dissolved, hence we see some difference in reported dissolutions compared to 
the previous SIL salt dissolution data reported (P Sanphui, S Tothadi, S Ganguly and G R Desiraju, 
2013, Mol Pharmaceutics, 10, 4687-4697).  
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Figure 12: Comparative solubility of SIL salts, cocrystals and hybrid salt-cocrystals in 0. 1N HCl (pH 
1.2) 
 
Figure 13: Comparative solubility of SIL salts, cocrystals and hybrid salt-cocrystals in phosphate 
buffer pH 6.5 
 24 
 
Figure 14: Comparative solubility of SIL salts, cocrystals and hybrid salt-cocrystals in FaSSIF 
At pH 1.2 the amount dissolved from SIL salts was significantly higher than the cocrystals and HSC 
form. The HSCs except SIL-3,4-DHBA I showed poor dissolution performance compared to cocrystals. 
SIL-TAR I showed significantly high dissolution rate compared to SIL-CIT a commercially used salt of 
SIL. The D1hr and D24hrs values for SIL-TAR I was significantly higher than SIL-CIT. At pH 1.2 in the 
salt category SIL-TAR > SIL-3-HBA I > SIL-CIT. Though D1hr for SIL-RES II > SIL-QUE I and SIL –
QUE II.  It is interesting to note that the amount dissolved at pH 6.5 though was at least 10 times lower 
than the amount dissolved at pH 1.2. But amount of SIL dissolved was significantly higher than 
cocrystals and HSCs. Most of the cocrystals and HSCs did not provide any release of SIL at pH 6.5 or 
even in FaSSIF , which contains additive like lecithin is included in the dissolution media. The 
dissolution study demonstrates potential of SIL-TAR as a better alternative to SIL – CIT.  
4. CONCLUSIONS 
In summary, we have revisited the multicomponent solid form landscape of sildenafil by conducting 
a combined virtual and experimental screening. 23 new solid forms have been discovered and 
characterized and the intrinsic dissolution rate have been measured for some of the solid forms. 
However, none of them showed a better profile than the citrate salt. The analysis of the five crystal 
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structures solved by SXRD showed a variety of salts and hybrid salt/cocrystals with different hydrogen 
bond architectures and presence of solvent channels. This study extends the knowledge about the solid 
state of this important drug compound, contributes with new cases to the body of data of unexpected 
stoichiometric hybrid salt/cocrystals and it is a new example of successful application of combined 
virtual/experimental methodologies for the discovery of new solid forms. 
 
5. SUPPORTING INFORMATION  
Synthesis of different crystal forms. Crystal data and structure refinement. Cocrystal Screening 
experiments. Characterization of the solids: DSC and TGA thermograms, PXRD diffractograms, 
1
H-
NMR spectra of new crystal forms. This material is available free of charge via the Internet at 
http://pubs.acs.org 
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SYNOPSIS TOC. New multicomponent solid forms of Sildenafil have been discovered by means of a 
combined virtual/experimental cocrystal screening. Coformer selection of candidates was conducted 
based on an in silico screening method from a database of more than 2000 organic compounds and the 
intensive experimental screen produced 24 new solid forms. Since the 12 coformers chosen have a 
combination of phenol and carboxylic acid groups a variety of cocrystals, salts and hybrid 
salt/cocrystals were discovered and characterized. 
